Dasatinib

Dasatinib
Clinical data
Trade namesSprycel, Dasanix
AHFS/Drugs.comMonograph
MedlinePlusa607063
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth (tablets)
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)[1]
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only[2]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding96%
MetabolismLiver
Elimination half-life1.3 to 5 hours
ExcretionFecal (85%), kidney (4%)
Identifiers
  • N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-
    1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazole
    carboxamide monohydrate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.228.321 Edit this at Wikidata
Chemical and physical data
FormulaC22H26ClN7O2S
Molar mass488.01 g·mol−1
3D model (JSmol)
  • Cc1cccc(c1NC(=O)c2cnc(s2)Nc3cc(nc(n3)C)N4CCN(CC4)CCO)Cl
  • InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27) checkY
  • Key:ZBNZXTGUTAYRHI-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Dasatinib, sold under the brand name Sprycel among others, is a targeted therapy medication used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).[3] Specifically it is used to treat cases that are Philadelphia chromosome-positive (Ph+).[3] It is taken by mouth.[3]

Common adverse effects include low white blood cells, low blood platelets, anemia, swelling, rash, and diarrhea.[3] Severe adverse effects may include bleeding, pulmonary edema, heart failure, and prolonged QT syndrome.[3] Use during pregnancy may result in harm to the baby.[3] It is a tyrosine-kinase inhibitor and works by blocking a number of tyrosine kinases such as Bcr-Abl and the Src kinase family.[3]

Dasatinib was approved for medical use in the United States and in the European Union in 2006.[3][2] It is on the World Health Organization's List of Essential Medicines.[4]

  1. ^ "Sprycel (Dasatinib)" (PDF). Therapeutic Goods Administration (TGA). Retrieved 18 July 2020.
  2. ^ a b "Sprycel EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 28 April 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  3. ^ a b c d e f g h "Dasatinib". The American Society of Health-System Pharmacists. Retrieved 8 December 2017.
  4. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.